• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Vaccine . Cost-effectiveness of free influenza vaccination policy for Chinese older adults: a modeling analysis using real-world data

tetano

Editor, Senior Moderator
Vaccine


. 2026 Jun 5:88:128782.
doi: 10.1016/j.vaccine.2026.128782. Online ahead of print.
Cost-effectiveness of free influenza vaccination policy for Chinese older adults: a modeling analysis using real-world data

Xiaoqing Wu[SUP] 1 [/SUP], Yumin Tao[SUP] 2 [/SUP], Yexiang Sun[SUP] 3 [/SUP], Jieping Chen[SUP] 4 [/SUP], Mengqian Lv[SUP] 4 [/SUP], Tianchi Yang[SUP] 5 [/SUP], Lixia Ye[SUP] 6 [/SUP]


Affiliations
Abstract

Objective: Vaccination serves as the most efficacious intervention to prevent influenza-related illness. The aim of this study was to compare the lifetime cost-effectiveness of a fully-funded trivalent inactivated influenza vaccine (TIV) strategy for people aged 60 years and over.
Methods: A static decision-tree Markov model was employed to conduct a lifetime economic evaluation from a societal perspective. Model parameters such as probabilities, costs and utility values, were derived from regional health information platform, published literature, and investigation. The number of cases and deaths averted, quality-adjusted life years (QALYs) gained, and the incremental cost-effectiveness ratio (ICER) were predicted. Sensitivity analyses were performed to evaluate the uncertainty of results.
Results: Compared with self-paid vaccination, the implementation of the free influenza vaccination program is projected to cumulatively reduce 261,374 non-medically attended influenza cases,370,155 outpatient influenza cases, 13,678 hospitalized influenza cases, and 1987 influenza-associated deaths. It is estimated that this programme will generate cumulative cost savings of $2,184,312 and an additional 14,324 QALYs, rendering it a dominant strategy. At a willingness-to-pay (WTP) threshold of one times of the per capita gross domestic product (GDP) of Ningbo, the probability of the programme being cost-effective is 99.88%. The threshold analysis revealed that the threshold price of TIV is $11.18 under the most conservative WTP threshold.
Conclusions: It has been demonstrated that the free influenza vaccination policy are cost-effective for the elderly individuals. The government and health authorities are supposed to implement and promote a universal free influenza vaccination programme for the elderly, with particular emphasis on the oldest age groups.

Keywords: Cost-effectiveness; Free vaccination policy; Older adults; TIV.

 
Back
Top